Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Secukinumab by Novartis for Unspecified Dermatological Disorders: Likelihood of Approval
Secukinumab is under clinical development by Novartis and currently in Phase II for Unspecified Dermatological Disorders. According to GlobalData, Phase...
Secukinumab by Novartis for Coronavirus Disease 2019 (COVID-19) Pneumonia: Likelihood of Approval
Secukinumab is under clinical development by Novartis and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia. According to...
Secukinumab by Novartis for Congenital Ichthyosis: Likelihood of Approval
Secukinumab is under clinical development by Novartis and currently in Phase II for Congenital Ichthyosis. According to GlobalData, Phase II...
Secukinumab by Novartis for Polymyalgia Rheumatica (PMR): Likelihood of Approval
Secukinumab is under clinical development by Novartis and currently in Phase III for Polymyalgia Rheumatica (PMR). According to GlobalData, Phase...
Secukinumab by Novartis for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair): Likelihood of Approval
Secukinumab is under clinical development by Novartis and currently in Phase II for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair). According...